2026 PTCE® Exam Blueprint Updates

In January 2026, the PTCB^® introduced an updated exam blueprint for the PTCE^® exam. The revised blueprint was designed to ensure that the exam reflects the knowledge needed for safe practice in today’s pharmacy environment. The revisions included updated weightings for each of the knowledge domains covered on the exam, the addition of new protocols and updated terminology, and the removal of a handful of topics. These updates went into effect after the publication of Barron’s book. However, rest assured that Barron’s PTCE: Pharmacy Technician Certification Exam Premium remains an invaluable resource, providing expert review and targeted practice that focuses on topics likely to be seen on the PTCE exam. 

Please see below for more detailed information regarding the blueprint changes. For the latest information, please visit the PTCB website.

Note: The exam format has not changed.

The updated exam blueprint is as follows:

Note: The Federal Requirements domain saw the largest growth in this update, increasing from 12.5% to 18.75%, while the Order Entry and Processing domain saw a slight increase from 21.25% to 22.5%. In addition, the Medications domain weighting decreased from 40% to 35%, and the Patient Safety and Quality Assurance domain saw a small reduction from 26.25% to 23.75%. These shifts reflect the exam’s increased focus on regulatory compliance and modern pharmacy technology.

Exam Update Details

• There is a new focus on managing “3T” documentation (Transaction Information, Transaction History, and Transaction Statements) and protocols for reporting illegitimate or suspect products. Test takers should be familiar with the Drug Supply Chain Security Act (DSCSA). 
• There is increased emphasis on the use of barcode-scanning workflows, Automated Dispensing Cabinets (ADCs), and other forms of technology as safety checks to prevent errors. 
• The term “therapeutic duplication” has replaced “therapeutic equivalence.” With this change comes a greater focus on clinical safety, specifically spotting when a patient is taking multiple medications with the same effect or from the same class.
• VAERS is now included alongside MedWatch. Test takers need to know the distinction between the two: MedWatch is for medications and medical products, whereas VAERS is strictly for vaccine-related adverse events. 
• The term “post-immunization delivery care” has replaced “post-immunization follow-up.” This change reflects a broader scope of patient care following vaccine administration. 
• To better reflect the latest practices and standards, the following topics have been retired from the PTCE exam:

1. Alligation Math: The “tic-tac-toe” method is no longer tested. However, calculating doses and days’ supply remain vital core skills. 
2. NTI and Incompatibilities: Standalone lists for Narrow Therapeutic Index (NTI) medications and physical/chemical incompatibilities have been eliminated. 
3. Non-Sterile Compounding Procedures: Manual mixing mechanics have been removed. The PTCE exam now prioritizes broad quality assurance and safety principles. 
4. Certain Equipment and Supplies: Package size and unit-dose information have been removed. However, pharmacy math, sig codes, and reverse distribution protocols are still tested on the PTCE exam.

PTCE^® is a registered trademark of the Pharmacy Technician Certification Board, which neither sponsors nor endorses this product.